FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
Clinical Scorecard: FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
At a Glance
Category Detail
Condition Sanfilippo Syndrome Type A Key Mechanisms AAV9 gene therapy delivering a functional copy of SGSH to restore sulfamidase production. Target Population Pediatric patients with preserved neurodevelopmental function. Care Setting Clinical treatment for neurological manifestations of mucopolysaccharidosis type IIIA.
Key Highlights
Fayuvi (rebisufligene etisparvovec-hopf) is the first FDA-approved treatment for Sanfilippo syndrome type A. The therapy aims to restore enzyme function and reduce heparan sulfate accumulation. In treated patients, a mean increase of 16 points in cognitive scores was observed compared to a decline in untreated patients. Common adverse reactions include elevated liver enzymes in 85% of patients. Patients require corticosteroid treatment and monitoring post-infusion. Guideline-Based Recommendations
Diagnosis
Diagnosis of MPS IIIA based on clinical and genetic criteria. Management
Administer Fayuvi as a one-time intravenous infusion. Monitoring & Follow-up
Monitor liver enzymes and other potential adverse reactions post-treatment. Risks
Potential risks include thrombocytopenia, infusion reactions, thrombotic microangiopathy, and malignancy from vector DNA integration. Patient & Prescribing Data
Children diagnosed with Sanfilippo syndrome type A and preserved neurodevelopmental function.
Requires corticosteroid treatment before and after infusion.
Clinical Best Practices
Conduct thorough monitoring of liver function and neurological status post-treatment. Utilize external natural history cohorts for comparative analysis due to the rarity of the disease. Related Resources & Content
